Developing vaccines against potential pandemic influenza viruses

J. M. Wood*, K. G. Nicholson, Maria Zambon, R. Hinton, D. L. Major, R. W. Newman, U. Dunleavy, D. Melzack, J. S. Robertson, G. C. Schild

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)


    In the event of an influenza pandemic, there will be an urgent need for a vaccine. The human infections with influenza A (H5N1) and A (H9N2) viruses served as pandemic warnings and initiated worldwide efforts to develop suitable vaccines. This was not straightforward however, due to safety considerations and many practical problems that were encountered. This is primarily on account of the three main strategies for H5 vaccine development: attenuation of the pathogenic A/Hong Kong/97 (H5N1) virus; expression of H5 haemagglutinin in baculovirus vectors; use of avirulent H5 avian viruses. Progress with H9 vaccine development is also reviewed. Over the past 2[formula omitted] years, we have learnt a great deal about our ability to respond to an influenza pandemic. Some of the improvements that could be made for the future, are summarised.

    Original languageEnglish
    Pages (from-to)751-759
    Number of pages9
    JournalInternational Congress Series
    Issue numberC
    Publication statusPublished - 1 Oct 2001


    • H5N1 vaccines
    • H9N2 vaccines


    Dive into the research topics of 'Developing vaccines against potential pandemic influenza viruses'. Together they form a unique fingerprint.

    Cite this